Group 1 - The core point of the news is the initiation of a Phase III clinical trial for Huangjia Suohan Granules, aimed at evaluating its efficacy and safety in treating chronic hepatitis B-related liver fibrosis [1][2] - The Phase III trial will include 480 participants and is designed as a randomized, double-blind, placebo-controlled, multi-center study [1] - The results from the completed Phase II trial indicated that Huangjia Suohan Granules have good clinical efficacy and safety, with patient benefits outweighing potential risks [1] Group 2 - There are four other traditional Chinese medicines undergoing clinical trials for liver fibrosis, indicating a competitive landscape in this therapeutic area [2] - Weikang Pharmaceutical, headquartered in Lishui, Zhejiang, focuses on the research, production, and sales of modern Chinese and Western medicines, with a strong emphasis on antibiotic and gynecological drug development [2] - The company's main products include Yinhuang Diban, Yimucao Soft Capsules, and other traditional Chinese medicines, as well as Western medicines like Roxithromycin Soft Capsules [2] Group 3 - Following the announcement of the Phase III trial, Weikang Pharmaceutical's stock price surged, with an increase of over 13% at one point, closing with a gain of 9.83% [3]
维康药业携手19家临床中心 启动黄甲软肝颗粒临床三期试验